Analysts Are Upgrading LENZ Therapeutics, Inc. (NASDAQ:LENZ) After Its Latest Results [Yahoo! Finance]
LENZ Therapeutics, Inc. (LENZ)
Company Research
Source: Yahoo! Finance
Revenues of US$13m beat estimates by a substantial 169% margin. Unfortunately, LENZ Therapeutics also reported a statutory loss of US$0.59 per share, which at least was smaller than the analysts expected. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. So we collected the latest post-earnings statutory consensus estimates to see what could be in store for next year. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. NasdaqGS:LENZ Earnings and Revenue Growth November 8th 2025 After the latest results, the seven analysts covering LENZ Therapeutics are now predicting revenues of US$53.4m in 2026. If met, this would reflect a huge 205% improvement in reven
Show less
Read more
Impact Snapshot
Event Time:
LENZ
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LENZ alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LENZ alerts
High impacting LENZ Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
LENZ
News
- LENZ Therapeutics Announces MFDS Submission of New Drug Application for LNZ100 (VIZZ™) in South Korea for the Treatment of PresbyopiaGlobeNewswire
- LENZ Therapeutics to Present at Upcoming Investor Conferences [Yahoo! Finance]Yahoo! Finance
- LENZ Therapeutics to Present at Upcoming Investor ConferencesGlobeNewswire
- LENZ Therapeutics (NASDAQ:LENZ) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.MarketBeat
- Insider Spends US$239k Buying More Shares In LENZ Therapeutics [Yahoo! Finance]Yahoo! Finance
LENZ
Earnings
- 11/5/25 - Beat
LENZ
Sec Filings
- 11/19/25 - Form 4
- 11/17/25 - Form 144
- 11/14/25 - Form SCHEDULE
- LENZ's page on the SEC website